Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Article

Aurora B kinase promotes CHIP-dependent degradation of HIF1a in prostate cancer cells

Kuntal Biswas, Sukumar Sarkar, Neveen Said, David L. Brautigan and James M. Larner
Kuntal Biswas
1Radiation Oncology, University of Virginia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sukumar Sarkar
2Radiation Oncology, University of Virginia School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neveen Said
3Cancer Biology, Wake Forest University School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David L. Brautigan
4Center for Cell Signaling and Department of Microbiology, Immunology & Cancer Biology, University of Virginia School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James M. Larner
2Radiation Oncology, University of Virginia School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jml2p@virginia.edu
DOI: 10.1158/1535-7163.MCT-19-0777
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Hypoxia is a major factor in tumor progression and resistance to therapies, which involves elevated levels of the transcription factor HIF-1a. Here we report that prostate tumor xenografts express high levels of HIF-1a and show greatly enhanced growth in response to knockdown of the E3 ligase CHIP (C-terminus of Hsp70-interacting protein). In multiple human prostate cancer cell lines under hypoxia taxol treatment induces the degradation of HIF-1a and this response is abrogated by knockdown of CHIP, but not by E3 ligase VHL or RACK1. HIF-1a degradation is accompanied by loss-of-function, evidenced by reduced expression of HIF-1a dependent genes. CHIP-dependent HIF-1a degradation also occurs in cells arrested in mitosis by nocodazole instead of taxol. Mitotic kinase Aurora B activity is required for taxol-induced HIF-1a degradation. Purified Aurora B directly phosphorylates HIF-1a at multiple sites and these modifications enhance its polyubiquitination by CHIP in a purified reconstituted system. Our results show how activation of Aurora B promotes CHIP-dependent degradation of HIF-1a in prostate cancer cells. This new knowledge may impact the use of mitotic kinase inhibitors and open new approaches for treatment of hypoxic prostate tumors.

  • Received August 8, 2019.
  • Revision received September 25, 2019.
  • Accepted December 12, 2019.
  • Copyright ©2019, American Association for Cancer Research.
Next
Back to top

This OnlineFirst version was published on December 17, 2019
doi: 10.1158/1535-7163.MCT-19-0777

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Aurora B kinase promotes CHIP-dependent degradation of HIF1a in prostate cancer cells
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Aurora B kinase promotes CHIP-dependent degradation of HIF1a in prostate cancer cells
Kuntal Biswas, Sukumar Sarkar, Neveen Said, David L. Brautigan and James M. Larner
Mol Cancer Ther December 17 2019 DOI: 10.1158/1535-7163.MCT-19-0777

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Aurora B kinase promotes CHIP-dependent degradation of HIF1a in prostate cancer cells
Kuntal Biswas, Sukumar Sarkar, Neveen Said, David L. Brautigan and James M. Larner
Mol Cancer Ther December 17 2019 DOI: 10.1158/1535-7163.MCT-19-0777
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Anti-invasive and antimetastatic effects of JZL184
  • Anti-CD19 CAR with favorable efficacy to toxicity balance
  • EYA3 in Ewing sarcoma growth and angiogenesis
Show more Research Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement